Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Phase II, Single Arm Study to Evaluate the Safety, Immunogenicity, Pharmacokinetics and Efficacy of rhC1INH for the Treatment of Acute Attacks in Pediatric Patients With Hereditary Angioedema, From 2-13 Years of Age

NCT01359969 is registered in ClinicalTrials.gov with Pharming Technologies B.V. as lead sponsor.

NCT NCT01359969
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01359969 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Phase II, Single Arm Study to Evaluate the Safety, Immunogenicity, Pharmacokinetics and Efficacy of rhC1INH for the Treatment of Acute Attacks in Pediatric Patients With Hereditary Angioedema, From 2-13 Years of Age
Lead sponsor
Pharming Technologies B.V.
Phase
Phase 2
Overall status
Completed
Start date
January 17, 2012
Completion date
July 17, 2017
Enrollment
57 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema